Filtered By:
Therapy: Cancer Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6 results found since Jan 2013.
TLR3 Ligand PolyI:C Prevents Acute Pancreatitis Through the Interferon- β/Interferon-α/β Receptor Signaling Pathway in a Caerulein-Induced Pancreatitis Mouse Model
In this study, we have found that polyI:C pretreatment prevents caerulein-induced pancreas edema, neutrophil infiltration, the accumulation of ROS, and inflammatory gene expression in the AP mice models. PolyI:C-triggered IFN-β production and downstream IFNAR signaling activation are required for the suppressive effect of polyI:C in the caerulein-induced AP model. Our study has not only demonstrated the protective role of polyI:C in limiting AP, but has also suggested a potential application of TLR3 ligands in the treatment of AP.
Materials and Methods
Mice and Reagents
Ifnb−/− mice and Ifnar1&#x...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research
Distinct Tumor Microenvironment at Tumor Edge as a Result of Astrocyte Activation Is Associated With Therapeutic Resistance for Brain Tumor
This study demonstrated that the vessels at the tumor edge are heterogeneous. The transient hypoxia at the tumor edge as the result of the appearance of immature NG2-CD31+ vessels is likely one reason for the radiochemoresistance of brain tumor. Although the heterogeneity of tumor oxygenation in space and time is well-recognized, this study is the first to report two spatially and functionally distinct types of tumor hypoxia in brain tumors, namely peripheral and central hypoxia.
As cancer cells frequently proliferate faster than parenchyma, such as endothelia, tumor progression is frequently accompanied with the deve...
Source: Frontiers in Oncology - April 25, 2019 Category: Cancer & Oncology Source Type: research
Hepatoma-Derived Growth Factor and DDX5 Promote Carcinogenesis and Progression of Endometrial Cancer by Activating β-Catenin
Conclusion: Our results provide novel evidence that HDGF interacts with DDX5 and promotes the progression of EC through the induction of β-catenin.
Introduction
Endometrial cancer (EC) comprises the most common malignancy involving the female genital tract and the fourth most common malignancy in women after breast, lung, and colorectal cancers (1). In 2012, approximately 320,000 new cases of EC were diagnosed worldwide and the incidence is increasing (2). Currently, endometrial carcinogenesis is thought to be a multi-step process involving the coordinated interaction of hormonal regulation, gene mutation, ad...
Source: Frontiers in Oncology - April 10, 2019 Category: Cancer & Oncology Source Type: research
Measuring Development of Adolescent and Young Adult Cancer Patients: An Integrative Review of Available Instruments.
Abstract
Adolescents and young adults (AYAs) 15-39 years old face unique challenges during cancer treatment as developmental and social needs are often disrupted to achieve cure. Developmentally appropriate supportive care for AYAs across the cancer trajectory is needed. The purpose of this review is to identify and describe instruments that measure AYA development across physical, psychological, and social domains, commenting on the instruments' psychometric properties and usefulness in clinical practice and research. A computerized literature search published in English from 1950 to January of 2017 was conducted...
Source: Ann Oncol - February 9, 2018 Category: Cancer & Oncology Authors: Bell CJ, Bell RA, Zebrack B, Kato I, Morse A, Borinstein SC Tags: J Adolesc Young Adult Oncol Source Type: research
Skyline Medical to take 20% stake in Helomics, license Illumina ’ s gene sequencing tech
Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN).
Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which combined with its existing right to convert a $500,000 loan would give it a 25% stake in the Pittsburgh-based precision diagnostics and contract research firm. Yesterday’s $1.14 closing price for Skyline stock would valu...
Source: Mass Device - December 20, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Diagnostics Genomics Molecular Diagnostics Mergers & Acquisitions Helomics Illumina Inc. Skyline Medical Source Type: news
Department of Defense Doubles Cancer Research Funding in 2015
Doctors and researchers seeking a cure for mesothelioma will soon be able to tap into millions of dollars set aside by the U.S. Department of Defense for cancer research.
The Office of Congressionally Directed Medical Research Programs (CDMRP) invested $50 million in the Peer Reviewed Cancer Research Program (PRCRP) for 2015 — an amount that doubles the money awarded to the program last year.
With the additional funding, asbestos-related cancer researchers can extend current studies and launch new ones to improve traditional treatments, introduce emerging therapies or test new cancer drugs. Funding in 2014 was $25 milli...
Source: Asbestos and Mesothelioma News - February 5, 2015 Category: Environmental Health Authors: Walter Pacheco Tags: Research & Clinical Trials Source Type: news
